Raymond James on Kalaris (KLRS): 'We continue to expect Kalaris to resume dosing in 2Q26 '

May 12, 2026 12:21 PM

Raymond James analyst Chris Raymond reiterated a Strong Buy rating and $23.00 price target on Kalaris (NASDAQ: KLRS).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found